FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and Oropharynx

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Dutra, Roberta Lelis ^a   de Carvalho, Marcos Brasilino ^b   Santos, Marcelo dos ^c   Mercante, Ana Maria da Cunha ^b   Gazito, Diana ^d   de Cicco, Rafael ^e   Group, GENCAPO ^f   Tajara, Eloiza Helena ^g   Louro, Iúri Drumond ^c   da Silva, Adriana Madeira Álvares ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL HELIÓPOLIS   (Brazil)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^d Associação Beneficente de Coleta de Sangue São Paulo   (Brazil)

^e IM IN JK) Inst Do C   (Brazil)

^f GENCAPO   (Brazil)

^g FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 4; PARAFFIN; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 4 GENE; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TISSUE MICROARRAY;

CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; TUMOR MARKERS, BIOLOGICAL;

EID: 84870671652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050747     Document Type: Article

References (44)

1. Burke D, Wilkes D, Blundell TL, Malcolm S, (1998) Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci 23: 59-62.
2. Powers CJ, McLeskey SW, Wellstein A, (2000) Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197.
3. Jeffers M, LaRochelle WJ, Lichenstein HS, (2002) Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 6: 469-482.
4. Cappellen D, de Oliveira C, Ricol D, de Medina S, Bourdin J, et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20.
5. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, et al. (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24: 5218-5225.
6. López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, et al. (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401-7404.
7. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL, (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109: 69-78.
8. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, et al. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62: 840-847.
9. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, et al. (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111: 213-217.
10. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, et al. (2003) Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98: 2245-2250.
11. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, et al. (2005) Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23: 7307-7311.
12. da Costa Andrade V, Parise O, Hors C, Martins P, Silva A, et al. (2007) The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 82: 53-57.
13. Frullanti E, Berking C, Harbeck N, Jézéquel P, Haugen A, et al. (2011) Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 20: 340-347.
14. Marmé F, Hielscher T, Hug S, Bondong S, Zeillinger R, et al. (2012) Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer 131: E586-E591.
15. Becker N, Nieters A, Chang-Claude J, (2003) The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer. Cancer Epidemiol Biomarkers Prev 12: 582-583.
16. Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, et al. (2004) G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 90: 189-193.
17. Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, et al. (2005) FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 14: 415-419.
18. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C, (2006) FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 94: 1879-1886.
19. Ragin CC, Modugno F, Gollin SM, (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86: 104-114.
20. Layland MK, Sessions DG, Lenox J, (2005) The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 115: 629-632.
21. Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours. sixth ed. John Wiley & Sons: New Jersey.
22. Miller SA, Dykes DD, Polesky HF, (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
23. Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E, (2001) Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 70: 255-264.
24. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, et al. (2002) Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 33: 968-974.
25. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, et al. (2002) Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 15: 1374-1380.
26. Soini Y, Kahlos K, Puhakka A, Lakari E, Saily M, et al. (2000) Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br J Cancer 3: 880-886.
27. Campos AH, Aldred VL, Ribeiro KC, Vassallo J, Soares FA, (2009) Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma. Mol Cell Biochem 321: 95-102.
28. Dailey L, Ambrosetti D, Mansukhani A, Basilico C, (2005) Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16: 233-247.
29. Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PL, (2010) Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1. Hepatology 52: 656-666.
30. Liwei L, Chunyu L, Jie L, Ruifa H, (2011) Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis. Urol Int 87: 159-164.
31. Olson DC, Deng C, Hanahan D, (1988) Fibroblast growth factor receptor 4, implicated in progression of islet cell carcinogenesis by its expression profile, does not contribute functionally. Cell Growth Differ 9: 557-564.
32. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G, (2007) N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signaling. Nat Cell Biol 3: 650-657.
33. Shah RN, Ibbitt JC, Alitalo K, Hurst HC, (2002) FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. Oncogene 21: 8251-8261.
34. Xu B, Tong N, Chen SQ, Hua LX, Wang ZJ, et al. (2011) FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC Cancer 11: 84.
35. Tanuma J, Izumo T, Hirano M, Oyazato Y, Hori F, et al. (2010) FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep 23: 739-744.
36. Seitzer N, Mayr T, Streit S, Ullrich A, (2010) A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 70: 802-812.
37. Tateno T, Asa SL, Zheng L, Mayr T, Ullrich A, Ezzat S, (2011) The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. Plos Genet 7: e1002400.
38. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.
39. Hurley JH, Lee S, Prag G, (2006) Ubiquitin-binding domains. Biochem J 399: 361-372.
40. Kirkin V, Dikic I, (2007) Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr Opin Cell Biol 19: 199-205.
41. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
42. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, et al. (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72: 3228-3237.
43. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, et al. (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24: 3747-3755.
44. Ansell A, Farnebo L, Grénman R, Roberg K, Thunell LK, (2009) Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 45: 23-29.